Evidence map›Paper›PMID 40573428›Full record

ArticleViruses2025

Serological Surveillance of Betacoronaviruses in Bat Guano Collectors: Pre-COVID-19 Pandemic and Post-SARS-CoV-2 Emergence.

Sasiprapa Ninwattana, Spencer L Sterling, Khwankamon Rattanatumhi, Nattakarn Thippamom, Piyapha Hirunpatrawong, Pakamas Sangsub, Thaniwan Cheun-Arom, Dominic Esposito, Chee Wah Tan, Wee Chee Yap and 5 more

Abstract read
In one paragraph

Article in Viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Sasiprapa NinwattanaThai Red Cross Emerging Infectious Diseases Clinical Center, King Chulalongkorn Memorial Hospital, Bangkok 10330, Thailand.
Spencer L SterlingHenry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD 20817, USA.ORCID 0000-0002-5924-4056
Khwankamon RattanatumhiThai Red Cross Emerging Infectious Diseases Clinical Center, King Chulalongkorn Memorial Hospital, Bangkok 10330, Thailand.ORCID 0000-0002-9260-5108
Nattakarn ThippamomThai Red Cross Emerging Infectious Diseases Clinical Center, King Chulalongkorn Memorial Hospital, Bangkok 10330, Thailand.
Piyapha HirunpatrawongThai Red Cross Emerging Infectious Diseases Clinical Center, King Chulalongkorn Memorial Hospital, Bangkok 10330, Thailand.ORCID 0000-0002-4803-8046
Pakamas SangsubThai Red Cross Emerging Infectious Diseases Clinical Center, King Chulalongkorn Memorial Hospital, Bangkok 10330, Thailand.
Thaniwan Cheun-AromDepartment of Biology, Faculty of Science, Ramkhamhaeng University, Bangkok 10240, Thailand.ORCID 0000-0003-2274-3385
Dominic EspositoProtein Expression Laboratory, Frederick National Laboratory for Cancer Research, NIH, Frederick, MD 21701, USA.ORCID 0000-0002-9987-1687
Chee Wah TanInfectious Diseases Translational Research Programme, Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117545, Singapore.
Wee Chee YapInfectious Diseases Translational Research Programme, Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117545, Singapore.
Feng ZhuProgramme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore 169857, Singapore.ORCID 0000-0002-8131-1219
Lin-Fa WangProgramme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore 169857, Singapore.ORCID 0000-0003-2752-0535
Eric D LaingDepartment of Microbiology and Immunology, Uniformed Services University, Bethesda, MD 20814, USA.ORCID 0000-0002-5574-2584
Supaporn WacharapluesadeeThai Red Cross Emerging Infectious Diseases Clinical Center, King Chulalongkorn Memorial Hospital, Bangkok 10330, Thailand.ORCID 0000-0001-7636-1900
Opass PutcharoenThai Red Cross Emerging Infectious Diseases Clinical Center, King Chulalongkorn Memorial Hospital, Bangkok 10330, Thailand.ORCID 0000-0001-8444-8512

Funding

WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6M
Understanding Risk of Zoonotic Virus Emergence in EID Hotspots of Southeast AsiaU01AI151797 · NIAID · ECOHEALTH ALLIANCE, INC. · PI DASZAK, PETER · 2020 to 2023
$6.0M
72nd anniversary of his Majesty King Bhumibol Aduladej ScholarshipACL HHS U01GH002402CGH CDC HHS U01 GH002402Graduate School, Chulalongkorn University, and the Global Health Research Promotion Grant from the School of Global Health, Faculty of Medicine, Chulalongkorn UniversityNational Institute of Allergy and Infectious Diseases of the National Institute of Health U01AI151797NCI NIH HHS 75N91019D00024NIAID NIH HHS U01 AI151797United States Agency for International Development (USAID) AID-OAA-A-14-00102
6 · The paper itself

Abstract

Community-based serosurveillance for emerging zoonotic viruses can provide a powerful and cost-effective measurement of cryptic spillovers. Betacoronaviruses, including SARS-CoV, SARS-CoV-2 and MERS-CoV, are known to infect bats and can cause severe respiratory illness in humans, yet remain under-surveyed in high-risk populations. This study aimed to determine the seroprevalence of betacoronaviruses in an occupational cohort in contact with bats before and after the emergence of SARS-CoV-2. Serum samples from pre- and post-COVID-19 pandemic were screened using antigen-based multiplex microsphere immunoassays (MMIAs) and a multiplex surrogate virus neutralization test (sVNT). Pre-pandemic samples showed no SARS-CoV-2 antibodies, while post-pandemic samples from vaccinated participants displayed binding and neutralizing antibodies against SARS-CoV-2 and a related bat CoV. Furthermore, one participant (1/237, 0.43%) had persistent antibodies against MERS-CoV in 2017, 2018 and 2021 but was seronegative in 2023, despite reporting no history of traveling abroad or severe pneumonia. The observed sustained antibody levels indicate a possible exposure to MERS-CoV or a MERS-CoV-like virus, although the etiology and clinical relevance of this finding remains unclear. Ongoing surveillance in high-risk populations remains crucial for understanding virus epidemiology and mitigating zoonotic transmission risk.

Indexed as

Antibodies, ViralChiropteraCOVID-19SARS-CoV-2AdultAnimalsAntibodies, NeutralizingFemaleHumansMaleMiddle AgedMiddle East Respiratory Syndrome CoronavirusPandemicsSeroepidemiologic StudiesZoonosesAntibodies, NeutralizingAntibodies, Viralbetacoronavirusesbinding antibodiesCOVID-19SARS-CoV-2surrogate neutralizing antibodieszoonotic spillovers

Identifiers

PMID40573428
PMCPMC12197454

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.